High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy

Treatment With the Radiolabeled Somatostatin Analog [ 177 Lu-DOTA 0 ,Tyr 3 ]Octreotate: Toxicity, Efficacy, and Survival

Kwekkeboom, D. J., de Herder, W. W., Kam, B. L. R., van Eijck, C. H. J., van Essen, M., Kooij, P. P. M., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,454 · see citing works

ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary

Pavel, M., Baudin, É., Couvelard, A., Krenning, E. P., Öberg, K., Steinmüller, T., Anlauf, M., Wiedenmann, B. J., & Salazar, R. (2012) · Neuroendocrinology · doi:10.1159/000335597 · Cited by 868 · see citing works

Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [ 90 Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers

Imhof, A., Brunner, P., Marincek, N., Briel, M., Schindler, C., Rasch, H. F., Mäcke, H. R., Rochlitz, C. F., Müller‐Brand, J., & Walter, M. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.7873 · Cited by 638 · see citing works

[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients

Kwekkeboom, D. J., Bakker, W. H., Kooij, P. P. M., Konijnenberg, M., Srinivasan, A., Erion, J. L., Schmidt, M. A., Bugaj, J. E., de Jong, M., & Krenning, E. P. (2001) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590100574 · Cited by 469 · see citing works

Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors

Bodei, L., Kidd, M., Paganelli, G., Grana, C. M., Drozdov, I., Cremonesi, M., Lepensky, C., Kwekkeboom, D. J., Baum, R. P., Krenning, E. P., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2893-5 · Cited by 465 · see citing works

Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course

Bergsma, H., Konijnenberg, M., Kam, B. L. R., Teunissen, J. J. M., Kooij, P. P. M., de Herder, W. W., Franssen, G. J. H., van Eijck, C. H. J., Krenning, E. P., & Kwekkeboom, D. J. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3193-4 · Cited by 177 · see citing works

Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate

Sabet, A., Ezziddin, K., Pape, U., Ahmadzadehfar, H., Mayer, K. T., Pöppel, T. D., Guhlke, S., Biersack, H., & Ezziddin, S. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.119347 · Cited by 164 · see citing works

Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)

Porta, M. G. D., Tuechler, H., Malcovati, L., Schanz, J., Sanz, G. F., Garcia‐Manero, G., Solé, F. G., Bennett, J. M., Bowen, D., Fenaux, P., et al. (2015) · Leukemia · doi:10.1038/leu.2015.55 · Cited by 134 · see citing works

Hematological Toxicity of Combined 177Lu-Octreotate Radiopeptide Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors in Long-Term Follow-Up

Kesavan, M., Claringbold, P. G., & Turner, J. H. (2014) · Neuroendocrinology · doi:10.1159/000362558 · Cited by 79 · see citing works

6LBA 177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: Results of the phase III NETTER-1 trial

Strosberg, J., Wolin, E. M., Chasen, B., Kulke, M. H., Bushnell, D. L., Caplin, M. E., Baum, R. P., Mittra, E., Hobday, T. J., Hendifar, A., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)31929-3 · Cited by 56 · see citing works

Can peptide receptor radionuclide therapy be safely applied in florid bone metastases?

Sabet, A., Khalaf, F., Yong-Hing, C. J., et al. (2014) · Nuklearmedizin - NuclearMedicine · doi:10.3413/nukmed-0614-13-08 · Cited by 31 · see citing works

Kann die Peptid-Radiorezeptortherapie bei diffuser Knochenmetastasierung noch sicher angewendet werden?

Sabet, A., Khalaf, F., Yong-Hing, C. J., et al. (2014) · Nuklearmedizin - NuclearMedicine · Cited by 16 · see citing works

Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

Garske-Román, U., Sandström, M., Fröss Baron, K., Lundin, L., Hellman, P., Welin, S., Johansson, S., Khan, T., Lundqvist, H., Eriksson, B., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-3945-z · Cited by 254 · see citing works

Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial

Del Prete, M., Buteau, F.-A., Arsenault, F., Saighi, N., Bouchard, L.-O., Beaulieu, A., & Beauregard, J.-M. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4209-7 · Cited by 184 · see citing works

Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning.

Cremonesi, M., Ferrari, M. E., Bodei, L., Chiesa, C., Sarnelli, A., Garibaldi, C., Pacilio, M., Strigari, L., Summers, P. E., Orecchia, R., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4044-x · Cited by 141 · see citing works

Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns

Wahl, R. L., Sgouros, G., Iravani, A., Jacene, H., Pryma, D., Saboury, B., Capala, J., & Graves, S. A. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262751 · Cited by 95 · see citing works

Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: Prognostic parameters and overall survival

Chantadisai, M., Kulkarni, H. R., & Baum, R. P. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05127-9 · Cited by 43 · see citing works

Myelodysplastic Syndromes (MDS)

Madanat, Y. F., & Sekeres, M. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-97873-4_27

The Effect of Fasting on Tissue Cyclic cAMP and Plasma Glucagon in the Obese Hyperglycemic Mouse

VINE, R. L. L., Voyles, N. R., Perrino, P. V., & Recant, L. (1975) · Endocrinology · doi:10.1210/endo-97-3-615 · Cited by 38 · see citing works

Exogenous Glucocorticoids and a High-Fat Diet Cause Severe Hyperglycemia and Hyperinsulinemia and Limit Islet Glucose Responsiveness in Young Male Sprague-Dawley Rats

Beaudry, J. L., D'souza, A. M., Teich, T., Tsushima, R. G., & Riddell, M. C. (2013) · Endocrinology · doi:10.1210/en.2012-2114 · Cited by 44 · see citing works

Erythroleukemia and Myelodysplastic Syndromes: An Historical Appraisal and aPersonalView

Michiels, J. J. (1993) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199309148500 · Cited by 9 · see citing works

Infections in myelodysplastic syndromes

Toma, A., Fenaux, P., Dreyfus, F., & Cordonnier, C. (2012) · Haematologica · doi:10.3324/haematol.2012.063420 · Cited by 119 · see citing works